エンテカビルの世界市場レポート 2025

エンテカビル市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR4.5％で8億9,000万米ドルに成長します。予測期間中の成長は、肝疾患対策への取り組みの増加、デジタルヘルスケアソリューションの導入拡大、ヘルスケアインフラの改善、健康保険の適用拡大、抗ウイルス薬の需要増などに起因すると考えられます。この期間の主な動向には、遺伝子検査の統合、高度な診断ツールの使用、個別化医療の進歩、併用療法の採用、モニタリング技術の進歩などが含まれます。

肝疾患の有病率の増加は、今後数年間のエンテカビル市場の成長を牽引すると予想されます。肝疾患には、感染症、遺伝的疾患、脂肪肝、肝炎、肝硬変、肝がんなどの生活習慣に関連する問題など、肝機能を損なうさまざまな疾患が含まれます。肝疾患の増加は、主にウイルス性肝炎（HBVおよびHCV）、肥満率の増加、アルコール乱用、代謝異常などの要因によるものです。抗ウイルス薬であるエンテカビルは、B型肝炎ウイルスの複製を効果的に阻害し、ウイルス量を減少させ、肝機能を改善し、肝硬変や肝がんのリスクを低下させることにより、肝疾患患者をサポートします。これは最終的に、慢性B型肝炎感染の管理とさらなる肝障害の予防に役立ちます。例えば、2024年6月、ビクトリア州がん評議会は、2022年に617人が肝臓がんと診断され、その67.9％が男性であったと報告しました。さらに、肝臓財団は、年間約3,000人が肝細胞がん（HCC）と診断されると予測しています。したがって、肝臓疾患の罹患率の上昇がエンテカビル市場の成長を促進しています。

B型肝炎の増加もエンテカビル市場を押し上げると予想されています。B型肝炎は肝臓を冒し、黄疸、疲労、腹痛などの症状を引き起こすウイルス感染症です。未治療の場合、慢性肝疾患や肝がんにつながる可能性があります。B型肝炎患者の増加は、無防備な性的接触、注射針の共有、出産時の母子感染、特定の地域における不十分なワクチン接種率などの要因に関連しています。エンテカビルは、B型肝炎ウイルス（HBV）DNAの複製を阻害し、ウイルス量を減少させ、肝障害を予防することにより、B型肝炎を治療します。例えば、2025年1月、英国健康安全保障庁は、2022年に英国で約27万人がB型肝炎に罹患しており、診断された患者数は2030年までに倍増すると予測していると報告しました。その結果、B型肝炎の有病率の増加がエンテカビル市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界エンテカビルPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のエンテカビル市場：成長率分析
• 世界のエンテカビル市場の実績：規模と成長, 2019-2024
• 世界のエンテカビル市場の予測：規模と成長, 2024-2029, 2034F
• 世界エンテカビル総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のエンテカビル市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• 経口溶液
• 世界のエンテカビル市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• B型肝炎の治療
• 肝臓移植
• その他の用途
• 世界のエンテカビル市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のエンテカビル市場錠剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標準用量錠剤
• 高用量錠
• 世界のエンテカビル市場経口液のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• すぐに使える液体溶液
• 経口溶液用粉末

第7章 地域別・国別分析

• 世界のエンテカビル市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のエンテカビル市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• エンテカビル市場：競合情勢
• エンテカビル市場：企業プロファイル
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • GSK plc Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Qingfeng Pharmaceutical Group Overview, Products and Services, Strategy and Financial Analysis
  • Aurobindo Pharma Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• ScinoPharm Taiwan Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Inc.
• Zhejiang Huahai Pharmaceuticals Co. Ltd.
• Qianjin Group
• Genix Pharma Ltd.
• Dawnrays Pharmaceutical Holidings Ltd.
• Zhejiang Ausun Pharmaceutical Co. Ltd.
• Hunan Warrant Chiral Pharmaceutical Co. Ltd.
• Camber Pharmaceuticals Inc.
• Century Pharmaceuticals Ltd.
• Aligos Therapeutics Inc.
• HRV Global Life Sceince
• Solco Healthcare LLC
• Accela ChemBio Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• エンテカビル市場2029：新たな機会を提供する国
• エンテカビル市場2029：新たな機会を提供するセグメント
• エンテカビル市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Entecavir is an antiviral medication used for the treatment of chronic hepatitis B. It works by inhibiting the replication of the hepatitis B virus, which helps lower the viral load. This, in turn, reduces the risk of severe liver damage and complications such as cirrhosis or liver cancer.

The primary forms of entecavir are tablets and oral solution. Entecavir tablets are taken orally and are prescribed for managing chronic hepatitis B (CHB) infection. These tablets are utilized for a range of purposes, including hepatitis B treatment, liver transplantation, and other related conditions. They are available through various distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The entecavir market research report is one of a series of new reports from The Business Research Company that provides entecavir market statistics, including the entecavir industry's global market size, regional shares, competitors with an entecavir market share, detailed entecavir market segments, market trends and opportunities, and any further data you may need to thrive in the entecavir industry. This entecavir market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The entecavir market size has grown strongly in recent years. It will grow from $0.71 billion in 2024 to $0.75 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth during the historical period can be attributed to several factors, including the increase in the incidence of hepatitis B, greater awareness of liver-related diseases, a growing emphasis on personalized medicine, the rise of online shopping for medications, and the improved availability of entecavir.

The entecavir market size is expected to see strong growth in the next few years. It will grow to $0.89 billion in 2029 at a compound annual growth rate (CAGR) of 4.5%. The growth during the forecast period can be attributed to increasing efforts to combat liver diseases, a rising adoption of digital healthcare solutions, improvements in healthcare infrastructure, greater health insurance coverage, and a growing demand for antiviral medications. Key trends during this period include the integration of genetic testing, the use of advanced diagnostic tools, advancements in personalized medicine, the adoption of combination therapies, and progress in monitoring techniques.

The increasing prevalence of liver diseases is expected to drive the growth of the entecavir market in the coming years. Liver diseases encompass a variety of conditions that impair liver function, including infections, genetic disorders, and lifestyle-related issues such as fatty liver, hepatitis, cirrhosis, and liver cancer. The rise in liver diseases is primarily attributed to factors such as viral hepatitis (HBV and HCV), increasing obesity rates, alcohol abuse, and metabolic disorders. Entecavir, an antiviral drug, supports liver disease patients by effectively inhibiting the replication of the hepatitis B virus, reducing viral load, improving liver function, and lowering the risk of cirrhosis and liver cancer. This ultimately helps manage chronic hepatitis B infections and prevents further liver damage. For example, in June 2024, the Cancer Council Victoria reported that 617 individuals were diagnosed with liver cancer in 2022, with 67.9% of cases affecting males. Additionally, the Liver Foundation projected that around 3,000 people are diagnosed with hepatocellular carcinoma (HCC) annually. Therefore, the rising incidence of liver diseases is driving the growth of the entecavir market.

The increasing prevalence of hepatitis B is also expected to boost the entecavir market. Hepatitis B is a viral infection that affects the liver, causing symptoms such as jaundice, fatigue, and abdominal pain. If untreated, it can lead to chronic liver disease or liver cancer. The rise in hepatitis B cases is linked to factors such as unprotected sexual contact, needle sharing, mother-to-child transmission during childbirth, and insufficient vaccination coverage in certain regions. Entecavir treats hepatitis B by inhibiting the replication of the hepatitis B virus (HBV) DNA, reducing viral load, and preventing liver damage. For instance, in January 2025, the UK Health Security Agency reported that approximately 270,000 people in the UK were living with hepatitis B in 2022, and the number of diagnosed cases is expected to double by 2030. Consequently, the growing prevalence of hepatitis B is driving the growth of the entecavir market.

Companies in the entecavir market are advancing clinical trials and innovative drug development for chronic hepatitis B treatment, aiming to improve efficacy and treatment outcomes while reducing resistance and enhancing long-term viral suppression. Clinical trials are essential for evaluating the safety and effectiveness of new treatments. For example, in October 2024, Aligos Therapeutics Inc., a US-based biotechnology company, initiated a phase 2 clinical trial for ALG-000184, a capsid assembly modulator being developed for hepatitis B treatment. ALG-000184 works by disrupting the formation of the capsid, the protective shell around a virus's genetic material. The ongoing study is assessing the long-term effects of ALG-000184, either alone or in combination with entecavir (sold as Baraclude), in patients with chronic hepatitis B. Preliminary results indicate that the combination of ALG-000184 and entecavir led to more significant reductions in viral load compared to entecavir alone, with ALG-000184 maintaining similar effectiveness regardless of its use alongside entecavir. The virus remained suppressed throughout the study in both HBeAg-positive and HBeAg-negative patients.

Major players in the entecavir market are Bristol-Myers Squibb Company, GSK plc, Teva Pharmaceutical Industries Ltd., Qingfeng Pharmaceutical Group, Aurobindo Pharma Ltd., ScinoPharm Taiwan Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Zhejiang Huahai Pharmaceuticals Co. Ltd., Qianjin Group, Genix Pharma Ltd., Dawnrays Pharmaceutical Holidings Ltd., Zhejiang Ausun Pharmaceutical Co. Ltd., Hunan Warrant Chiral Pharmaceutical Co. Ltd., Camber Pharmaceuticals Inc., Century Pharmaceuticals Ltd., Aligos Therapeutics Inc., HRV Global Life Sceince, Solco Healthcare LLC, Accela ChemBio Inc.

Asia-Pacific was the largest region in the entecavir market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in entecavir report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Entecavir market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The entecavir market consists of sales of generic versions, branded formulations, combination therapies, antiviral drugs, injectable formulations and over-the-counter antiviral supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Entecavir Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on entecavir market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for entecavir ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The entecavir market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Tablets; Oral Solution
• 2) By Application: Hepatitis B Treatment; Liver Transplantation; Other Applications
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Tablets: Standard Dose Tablets; High Dose Tablets
• 2) By Oral Solution: Ready-to-Use Liquid Solution; Powder For Oral Solution
• Companies Mentioned: Bristol-Myers Squibb Company; GSK plc; Teva Pharmaceutical Industries Ltd.; Qingfeng Pharmaceutical Group; Aurobindo Pharma Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Entecavir Market Characteristics

3. Entecavir Market Trends And Strategies

4. Entecavir Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Entecavir Growth Analysis And Strategic Analysis Framework

• 5.1. Global Entecavir PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Entecavir Market Growth Rate Analysis
• 5.4. Global Entecavir Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Entecavir Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Entecavir Total Addressable Market (TAM)

6. Entecavir Market Segmentation

• 6.1. Global Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Oral Solution
• 6.2. Global Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis B Treatment
• Liver Transplantation
• Other Applications
• 6.3. Global Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Entecavir Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Dose Tablets
• High Dose Tablets
• 6.5. Global Entecavir Market, Sub-Segmentation Of Oral Solution, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ready-to-Use Liquid Solution
• Powder For Oral Solution

7. Entecavir Market Regional And Country Analysis

• 7.1. Global Entecavir Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Entecavir Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Entecavir Market

• 8.1. Asia-Pacific Entecavir Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Entecavir Market

• 9.1. China Entecavir Market Overview
• 9.2. China Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Entecavir Market

• 10.1. India Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Entecavir Market

• 11.1. Japan Entecavir Market Overview
• 11.2. Japan Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Entecavir Market

• 12.1. Australia Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Entecavir Market

• 13.1. Indonesia Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Entecavir Market

• 14.1. South Korea Entecavir Market Overview
• 14.2. South Korea Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Entecavir Market

• 15.1. Western Europe Entecavir Market Overview
• 15.2. Western Europe Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Entecavir Market

• 16.1. UK Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Entecavir Market

• 17.1. Germany Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Entecavir Market

• 18.1. France Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Entecavir Market

• 19.1. Italy Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Entecavir Market

• 20.1. Spain Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Entecavir Market

• 21.1. Eastern Europe Entecavir Market Overview
• 21.2. Eastern Europe Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Entecavir Market

• 22.1. Russia Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Entecavir Market

• 23.1. North America Entecavir Market Overview
• 23.2. North America Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Entecavir Market

• 24.1. USA Entecavir Market Overview
• 24.2. USA Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Entecavir Market

• 25.1. Canada Entecavir Market Overview
• 25.2. Canada Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Entecavir Market

• 26.1. South America Entecavir Market Overview
• 26.2. South America Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Entecavir Market

• 27.1. Brazil Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Entecavir Market

• 28.1. Middle East Entecavir Market Overview
• 28.2. Middle East Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Entecavir Market

• 29.1. Africa Entecavir Market Overview
• 29.2. Africa Entecavir Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Entecavir Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Entecavir Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Entecavir Market Competitive Landscape And Company Profiles

• 30.1. Entecavir Market Competitive Landscape
• 30.2. Entecavir Market Company Profiles
  • 30.2.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GSK plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Qingfeng Pharmaceutical Group Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Aurobindo Pharma Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Entecavir Market Other Major And Innovative Companies

• 31.1. ScinoPharm Taiwan Ltd.
• 31.2. Dr. Reddy's Laboratories Ltd.
• 31.3. Cipla Inc.
• 31.4. Zhejiang Huahai Pharmaceuticals Co. Ltd.
• 31.5. Qianjin Group
• 31.6. Genix Pharma Ltd.
• 31.7. Dawnrays Pharmaceutical Holidings Ltd.
• 31.8. Zhejiang Ausun Pharmaceutical Co. Ltd.
• 31.9. Hunan Warrant Chiral Pharmaceutical Co. Ltd.
• 31.10. Camber Pharmaceuticals Inc.
• 31.11. Century Pharmaceuticals Ltd.
• 31.12. Aligos Therapeutics Inc.
• 31.13. HRV Global Life Sceince
• 31.14. Solco Healthcare LLC
• 31.15. Accela ChemBio Inc.

32. Global Entecavir Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Entecavir Market

34. Recent Developments In The Entecavir Market

35. Entecavir Market High Potential Countries, Segments and Strategies

• 35.1 Entecavir Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Entecavir Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Entecavir Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer